Loading…
Loading…
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, Sept. 16, 2026.Bernard Zovighian, chief executive officer, is scheduled to present at 10:00 a.m. ET. Doretta Mistras, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessibl.
Beacon Pointe Advisors LLC bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 128,603 shares of the medical research company's stock, valued at approximately $11,632,000. A number of
On August 26, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has seen a price performance of +12.4% over the past year
Bank of Nova Scotia bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 60,417 shares of the medical research company's stock, valued at approximately $5,465,000. Several other hedge funds also recently made
EP Wealth Advisors LLC bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 37,702 shares of the medical research company's stock, valued at approximately $3,410,000. Other institutional investors and hedge
B. Metzler seel. Sohn and Co. AG acquired a new position in Edwards Lifesciences Corporation (NYSE: EW) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 41,753 shares of the medical research company's stock, valued at approximately $3,777,000. Several other hedge
Allworth Financial LP bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 16,600 shares of the medical research company's stock, valued at approximately $1,502,000. A number of other hedge funds have also